Literature DB >> 14991605

The CD8+ T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity.

Joseph Lustgarten1, Ana Lucia Dominguez1, Camilo Cuadros1.   

Abstract

The majority of tumor-associated antigens are aberrantly expressed or overexpressed normal gene products. Therefore, mechanisms responsible for self tolerance dampen immune responses against these antigens. To evaluate the effect that tolerance has on the immune responses against tumor antigens, we characterized the CD8+ T cell responses in neu mice. T cell responses against the A2.1/neu p369-377 and p773-782 peptides were evaluated in neu mice that were crossed with A2.1/Kb transgenic mice (A2 x neu). Tetramer binding and cytotoxic activity demonstrate that, compared to CTL from A2.1/Kb x FVB wild-type mice (A2 x FVB), CD8+ T cells from A2 x neu mice were of lower avidity for the peptides. Despite the fact that A2 x neu mice are tolerant, multiple immunizations with DC pulsed with the p369-377 or p773-782 peptides in the presence of IL-2 retarded tumor growth in A2 x neu mice, and immunizations in combination with the anti-OX40 mAb further enhanced the antitumor response. Taken together, these data indicate that low-avidity T cells for neu antigens persisting in A2 x neu mice have the capacity to develop antitumor responses as long as they are provided with efficient costimulation. These results underscore the potential role of low-avidity T cells in antitumor immunity and may offer an important component for vaccination immunotherapies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14991605     DOI: 10.1002/eji.200324427

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  18 in total

1.  CCR5 in cancer immunotherapy: More than an "attractive" receptor for T cells.

Authors:  Alicia González-Martín; Emilia Mira; Santos Mañes
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

2.  Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer.

Authors:  Nicholas C Souders; Duane A Sewell; Zhen-Kun Pan; S Farzana Hussain; Alexander Rodriguez; Anu Wallecha; Yvonne Paterson
Journal:  Cancer Immun       Date:  2007-02-06

3.  Immunity, cancer and aging: lessons from mouse models.

Authors:  Cheryl E Myers; Noweeda N Mirza; Joseph Lustgarten
Journal:  Aging Dis       Date:  2011-12-02       Impact factor: 6.745

4.  Targeting the epidermal growth factor receptor (HER) family by T cell receptor gene-modified T lymphocytes.

Authors:  Peter Meyerhuber; Heinke Conrad; Lilian Stärck; Matthias Leisegang; Dirk H Busch; Wolfgang Uckert; Helga Bernhard
Journal:  J Mol Med (Berl)       Date:  2010-08-11       Impact factor: 4.599

5.  Chronic chemoimmunotherapy achieves cure of spontaneous murine mammary tumors via persistent blockade of posttherapy counter-regulation.

Authors:  Rachael B Rowswell-Turner; Jamie L Harden; Raji E Nair; Tao Gu; Mehmet O Kilinc; Nejat K Egilmez
Journal:  J Immunol       Date:  2011-09-09       Impact factor: 5.422

Review 6.  Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family.

Authors:  H Michael Shepard; Cathleen M Brdlik; Hans Schreiber
Journal:  J Clin Invest       Date:  2008-11       Impact factor: 14.808

7.  Targeting the tumor microenvironment with anti-neu/anti-CD40 conjugated nanoparticles for the induction of antitumor immune responses.

Authors:  Ana Lucia Dominguez; Joseph Lustgarten
Journal:  Vaccine       Date:  2009-11-18       Impact factor: 3.641

8.  Heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin enhances EphA2+ tumor cell recognition by specific CD8+ T cells.

Authors:  Mayumi Kawabe; Maja Mandic; Jennifer L Taylor; Cecilia A Vasquez; Amy K Wesa; Leonard M Neckers; Walter J Storkus
Journal:  Cancer Res       Date:  2009-08-18       Impact factor: 12.701

Review 9.  The role of OX40-mediated co-stimulation in T-cell activation and survival.

Authors:  William L Redmond; Carl E Ruby; Andrew D Weinberg
Journal:  Crit Rev Immunol       Date:  2009       Impact factor: 2.214

10.  Systemic targeting of CpG-ODN to the tumor microenvironment with anti-neu-CpG hybrid molecule and T regulatory cell depletion induces memory responses in BALB-neuT tolerant mice.

Authors:  Sanjay Sharma; Ana Lucia Dominguez; Soraya Zorro Manrique; Federica Cavallo; Shimon Sakaguchi; Joseph Lustgarten
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.